Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects
about
Preclinical models of antipsychotic drug action.The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophreniaActivation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake ratsBipolar disorder: candidate drug targets.Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?The effects of ketamine and risperidone on eye movement control in healthy volunteers.How Nox2-containing NADPH oxidase affects cortical circuits in the NMDA receptor antagonist model of schizophrenia.Targeting glutamate synapses in schizophreniaNicotine, Auditory Sensory Memory, and sustained Attention in a Human Ketamine Model of Schizophrenia: Moderating Influence of a Hallucinatory Trait.NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia.Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors.Neuromapping techniques in drug discovery: pharmacological MRI for the assessment of novel antipsychotics.Neurobiological background of negative symptoms.Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in ratsEffects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats.Modulation of the cortical processing of novel and target stimuli by drugs affecting glutamate and GABA neurotransmission.Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophreniaImpact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotionGlycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidenceGlutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeuticsKetamine and phencyclidine: the good, the bad and the unexpected.mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.mGlu2 metabotropic glutamate receptors restrain inflammatory pain and mediate the analgesic activity of dual mGlu2/mGlu3 receptor agonistsFrom revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.Glutamatergic model psychoses: prediction error, learning, and inferenceGroup II metabotropic glutamate receptor agonist LY379268 regulates AMPA receptor trafficking in prefrontal cortical neurons.Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia.NMDA receptor antagonist ketamine impairs feature integration in visual perceptionKetamine perturbs perception of the flow of time in healthy volunteers.Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia.Translating glutamate: from pathophysiology to treatment.Therapeutic potential of metabotropic glutamate receptor modulators.Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain functionNAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition test.Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation.Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans.From prediction error to psychosis: ketamine as a pharmacological model of delusions.
P2860
Q26827502-A1DD6453-0020-43CE-B06A-EAAADE1D9E98Q28081110-E509CFC2-0171-4278-9CAA-983F6734F1ECQ28297687-4069F8F6-4516-4166-AFBE-E0610FFFAFDDQ28751133-5D982A48-18C8-4B9E-A2BA-C5F26DAB68ADQ30379983-0278BEC8-3BD5-444C-AC28-8F8B79376A71Q30437913-7F1B881B-D3E9-4BF8-BAB8-204EE1E12ACCQ30439924-39DBA659-B80E-4E5A-92A9-B3FACBA9FBA7Q30460392-DBD229A0-2EE1-46DC-912F-D371CBFC890BQ30462575-15A17B65-4E82-4981-9884-C60AD1E4B7A0Q30465008-55557DFF-67DA-408D-B298-71FE056EEE59Q30473410-A4FDA4B5-BC03-4C7B-A561-4E49882BFBCEQ30491856-9DDB5871-7EEE-49BC-8A41-A6B24BED4709Q30564474-CAEF6AF3-605B-4FBD-8128-3DA0EAF7D49BQ30913824-567111BD-BC3D-425B-880B-B400CF130469Q33848200-FA448A5C-9F40-4F74-B140-3C8E08EC77F9Q33936354-2F247D72-1AAA-4C69-93E2-F7AB648E892DQ33975747-328E588A-0571-401A-93EE-24FD634E6430Q33976994-4E571829-7E39-41F8-8EEA-24C93336424FQ34197072-70825CDA-AF1F-4201-8F7C-73296BBA8CFCQ34235541-8C477855-575A-42D8-9FBB-579EAE3A80FDQ34330678-1497E827-F009-4B84-AEEB-6D28C0D0B4F9Q34444632-558F608F-FF52-4B11-BF61-64C0F86A34FEQ34480719-27062B13-49C9-4A84-841A-E671A1C7C9A5Q34513221-B2720B13-A1CD-44C2-ACD0-33613A975767Q34537679-7855A5FA-B479-4382-821A-96F60D0DEC56Q34632695-85F0F228-A8BE-4471-B66E-F41670B24FCEQ34661231-092E0EA0-044B-4084-A7DF-D5668B0967D1Q34675038-900C1590-84EC-40FC-9F34-D17AFF88125BQ34988708-28D3C20B-A057-4BF8-9193-5D22A00589B6Q35041262-6EE157EA-31FC-4D94-A421-404B6CB09AB7Q35534219-9AFDFBD7-41C6-4EBA-A9E1-600D0E08C2ABQ35547495-2A180FDF-FB66-4277-B477-9050666645B1Q35653538-6CC81C93-8C7D-4FFC-803F-2196B85D222CQ35739457-F24DD225-1572-417C-94E3-23F980256D42Q35778704-C9B28FA8-73FB-4EF4-9C4A-D848E9DF46B9Q35894585-A4F3A48B-4DB2-478E-B750-56781A689434Q36675499-0933BFCC-5AC4-4CC2-AA3F-9045E1BE63A5Q36687682-FC06589F-25FB-4121-BFAC-2466A86B0E42Q36821450-2BC4DC48-CF4D-4BE2-9E71-BC45C21D9B16Q36860032-312CE4CF-F7DA-4435-A6FD-893C0815941C
P2860
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Preliminary evidence of attenu ...... 740, in healthy human subjects
@ast
Preliminary evidence of attenu ...... 740, in healthy human subjects
@en
Preliminary evidence of attenu ...... 740, in healthy human subjects
@nl
type
label
Preliminary evidence of attenu ...... 740, in healthy human subjects
@ast
Preliminary evidence of attenu ...... 740, in healthy human subjects
@en
Preliminary evidence of attenu ...... 740, in healthy human subjects
@nl
prefLabel
Preliminary evidence of attenu ...... 740, in healthy human subjects
@ast
Preliminary evidence of attenu ...... 740, in healthy human subjects
@en
Preliminary evidence of attenu ...... 740, in healthy human subjects
@nl
P2093
P2860
P1433
P1476
Preliminary evidence of attenu ...... 740, in healthy human subjects
@en
P2093
Alan Breier
D Cyril D'Souza
Edward Perry
John H Krystal
Lisa McDougall
Louise Levine
Nianjin Liu
Tracy Hunsberger
Walid Abi-Saab
P2860
P2888
P356
10.1007/S00213-004-1982-8
P407
P577
2005-04-01T00:00:00Z
P6179
1011876778